New treatments for SLE: cell-depleting and anti-cytokine therapies
- 31 October 2005
- journal article
- review article
- Published by Elsevier BV in Best Practice & Research Clinical Rheumatology
- Vol. 19 (5), 859-878
- https://doi.org/10.1016/j.berh.2005.05.006
Abstract
No abstract availableKeywords
This publication has 93 references indexed in Scilit:
- B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximabArthritis & Rheumatism, 2004
- Elevated interleukin-18 levels correlated with disease activity in systemic lupus erythematosusClinical Rheumatology, 2004
- Anti-tumour necrosis factor (TNF) alpha treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13Annals Of The Rheumatic Diseases, 2002
- CD154–CD40 interactions mediate differentiation to plasma cells in healthy individuals and persons with systemic lupus erythematosusArthritis & Rheumatism, 2002
- Increased number of interleukin-10-producing cells in systemic lupus erythematosus patients and their first-degree relatives and spouses in Icelandic multicase familiesArthritis & Rheumatism, 1999
- CD20: a regulator of cell-cycle progression of B lymphocytesImmunology Today, 1994
- Interleukin 6 promotes murine lupus in NZB/NZW F1 mice.JCI Insight, 1994
- Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosusArthritis & Rheumatism, 1993
- Immunoregulation of SLE-like disease by the IL-1 receptor: Disease modifying activity on BDF1 hybrid mice and MRL autoimmune miceInflammation Research, 1993
- Chronic therapy with recombinant tumor necrosis factor-α in autoimmune NZB/NZW F1 miceClinical Immunology and Immunopathology, 1989